TO THE PROBLEM OF COMORBIDITY AND SYNTHROPY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Abstract
The study objective is to establish the relationships features between lipid profile and other parameters of homeostasis in case of chronic obstructive pulmonary disease in framework comorbidity with coronary artery disease and arterial hypertension. Materials and methods: the lipid profile, CRP, IgE, НbА1С, FEV1, Tiffno’s index and SpO2 in 35 patients with chronic obstructive pulmonary disease (groups B, C, D), that were studied by standard methods. Results: A large quantity of correlations between different indicators that increased in relation to disease progression and presence of comorbidity was found. Cluster analysis confirmed the affinity between these indicators. Conclusion: A large quantity of correlation links between lipids and other indices of homeostasis and the results of cluster analysis indicate the development of adaptation and disadaptation processes under such circumstances as elevation of hypoxia in chronic obstructive pulmonary disease and these might be evaluated as synthropy of comorbidity with coronary artery disease and arterial hypertension.
Downloads
References
Puzyrev V.P. Genetic Bases of Human Comorbidity. Genetika – Genetic 2015; 4: 491–495 (in Russ).
Vyatkin V.B. About application of the term «syntropy» in scientific research. Referativnyi zhurnal – Abstract journal 2016; 3: 81–84 (in Russ).
Shirinskiy V.S., Shirinskiy I.V. Comorbid diseases are animportant problem of the clinical medicine. Sibirskyi medicinskyi zhurnal – Siberian medical journal 2014; 29(1): 7–12 (in Russ).
Viliyasov V. B., Solovyeva N. V., Kremenitskaya S. A., Kuvshinova Y. V. Genetic syntropy or comorbidity? Clinical pathogenic analysis of the results of the patient study with monosomy 18p. The modern problem of the science and education. Elektronnyi naychnyi zhurnal – Electronic scientific journal 2017; 4: UPL; https: www.sciense-education.ru/ruarticle/view? id=26660 (in Russ).
Kutsenko M. A., Chuchalin A. G. Paradigm of the comorbidity: the COPD and IHD synthropy. Russkyimedicinskyizhurnal – Russian medical journal 2014; 22 (5): 389–392 (in Russ).
Marx P., Antal P., Bolgar B., Bagdy G., Deakin В., Juhazz G. Comorbidities in the diseasome are more apparent than real: what Bayesian filtering reveals about the comorbidities of depression. PLoS Comput Biol. 2017; 13 (6): e1005487.
Vanflettern L. E., Spruit M. F., Groenen M. Clusters of comorbidities based on validation objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J.Respir. Crit. Care Med. 2013; 187: 728–735.
Barabasi A. L. Network Medicine – from Obesity to the «Diseasome». N. Engl. J. Med. 2007; 357: 404–407.
Kalmikov O. O. Mechanisms of realisation of cardiorespiratory disturbanses in occupational diseases of bronchopulmonary system with accompanying coronary artery disease: diagnostic and prophylactic aspects. Dissertation synopsis for the degree of PhD, speciality 14.01.02 «Internal diseases», Kharkiv 2016; 40 p. (in Ukr).
Goh KI, Choi IG. Exploring the human diseasome: the human disease network. Briefings in Functional Genomics 2012; 11 (issue 6): 533–542.
COPD and Comorbidity. Ed. by Rabe KF, Wedzicha JA, Wouters EFM. European Respiratory Monograf 59, 2013; p.225.
Marshall VJ. Clinical biochemistry: translation from English. Edited by PhD Novikov NI – Moskov–St-Petersburg; 1999: 245–261 (in Russ).
Knyshova V. V, Gvozdenko T. A, Antonyuk M. V., Novgorodtseva T. P. Dyslipidemia phenotypes among patients with chronic disease of bronchopulmonary system. Bulletin phisiologii i patologii dikhaniya – Bulletin of physiology and breath pathology 2014; 51: 20–27 (in Russ).
Khristich T. N., Shestakova E. G., Teleki Ya. M., Gontsayruk D. A., Kushnir L. D. Comorbidity of the chronic obstructive pulmonary disease and coronary heart disease: peculiarities of pathogenic and management of patients (review of literature and own data). Ukrainskyi terapevticheskyi zhurnal – Ukrainian therapiutic journal 2013; 2: 101–108 (in Russ).
Slepchenko N., Mostovoy Y., Sidorov A. Is high level of IgE an additional problem in smoking patients with severe and very severe chronic obstructive pulmonare disease. Europ.Respir. Journ 2012; 40 (issue supple 56): 34–41.
Renkema T., Kerstjens H., Schouten J., Vonk J., Koster G., Postma D. The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in chronic obstructive pulmonare diseases. Clin. Exper. Allergy 1998; 28: 1210–1219.
Kukshekbaeva A. S., Nasonov E. L., Masab V. P. IgE in patients with ischemic heart disease. Klinicheskaya medicina – Clinical medicine 1990; 2: 36–38 (in Russ).
Korkmaz V. E., Oto A., Saraclar G., Oram E., Oram A., Ugurlu S.. Karamehmetoglu A., Karamehmetoglu E. Levels IgE in the serum of patients with coronary arterial disiese. Inf. J. Cardiol. 1991; 31: 199–204.
Wang J. Cheng X., Xiang MX. IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherosclerosis in Apoe mice. J. Clin. Inves. 2011; 121: 3564–3577.
Samaha H.MS. Total serum IgE in COPD patients. Egyptian Journ. of Chest Diseases and Tuberculosis 2015; 64 (Iss.3): 573–577.
Bot L., Shi G.P., Covanen P. Mast cells as effectors in atherosclerosis. Atheroscler. Thromb.Vasc. Biol. 2015; 35(2): 265–271.
Rana J., Mittelman M., Sheikh J., Hu F. COPD, astma and risk of type 2 diabetes in women. Diab etes care 2014; 27: 2478–2484.
Mannino D.M., Thorn D., Swensen A., Houlquin F. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: P. 765–773.
Titova E. A., Algasin A. I., Kornilova T. A. Features of the course of chronic pulmonary obstructive disease in patients with diabetes mellitus. Pulmonologiya – Pulmonology 2008; 5: 60–65 (in Russ)
Poulain M., Doucet M., Drapeua V. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary diseases. Chron. Respir. Dis. 2008; 5: 35–41.
Ryazanov A. S., Kireev S. A., Eremenko N. N. Features chronic obstructive pulmonary disease clinical course in case of metabolic syndrome: the role of systemic inflammation. Ozhirenie i metabolism – Obesity and metabolism 2010; 2: 49–51 (in Russ).
Lin W. Y., Yao C. A., Wang H. C. Impaired lung function is associated with obesity and metabolic syndrome in adults. Obesity (Silver Spring) 2006; 14: 1654–1661.
Marquis K., Maltais F., Duquay V. The metabolic syndrome in patient with chronic obstructive pulmonary disease. J. Cardiopulm. Rheabil. 2005; 25: 226–232.
Park S. K., Larson J. L. Metabolic syndrome and associated factors in people with Chronic Obstructive Pulmonary Disease. Western Journal of Nursing Research. 2014; 36(5): 620–642.
Eisner MD, Blanc PD, Sidney S. Body composition and functional limitation in chronic obstructive pulmonaire disease. Respir. Res. 2000; 7: 1–10.
Steuten L.M., Creutzberg E.C., Vrijoef H.J., Wonters F.F. COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim. Care Respir. J. 2006; 15: 84–91.
Shredinger E. What is life from the physics perspectives? Translation from English by Malinovskyi A. A., Moscow, RIMIS 2009; 176 (in Russ).
Malinetskii G. G. Theory of self-organization. On the cusp of IV paradigm. Komputerniye issledovaniya i modelirovanie – Computer research and modeling 2013; 3: 315–366 (in Russ).
Chernavskyi D. S. Synergetics and information (dynamic information theory). 2nd edition, UPSS 2017; 304 (in Russ).
von Seht L. Weiteres uber Syntropie kindlicher Krankheitszustande. Zeitschrift fur Kinderheilkunde 1922; 31(issue 5): 208–213.
van Eeden S. Leipsi S. J. The relationship between lung inflammation and cardiovascular disiese. Am.J. Respir. Crit.CareMed. 2012; 186 (1): 11–16.
Sin D. D, Man S. F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2 (1): 8–11.
van den Akken M., Buntix T., Roos S., Knottnerus J. A. Comorbidity or multimorbidity: what is a name? A review of literature. Eur. J. Gen. Pract.1996; 2(2): 65–70.
Fadieienko G. D., Kamenir V. M. Relationship of melatonin metabolites and nitric oxide in pathogenesis of gastroesophageal reflux disease in combination with chronic obstructive pulmonary disease. Ukrainskyi terapevticheskyi zhurnal – Ukrainian therapiutic journal 2009; 4: 78–87 (in Russ).
Wong C. Y., Chandry S. I., Desai M. M. Trends in comorbidity, disability, and polypharmacy in heart failure. Am. J. Med. 2011; 124: 136–143.
Shirinskiy V. S., Shirinskiy I. V. Hub therapy as a new opportunity for treatment of comorbid diseases. Sibirskyi medicinskyi zhurnal – Siberian medical journal 2014; 29(4): 13–21 (in Russ).
Gerasimova EB, Bazdyrev ED, Smakotina SA, Hryachkova ON, Soldatova NV. Efficiency of hypolipidemic therapy at patients with chronic obstructive pulmonary disease. Medicina i obrasovanie v Sibiri – Medicine and education in Sibiria 2014; 2: http://ngmu.ru/cozo/mos/article/text_full.php?id=1304 (in Russ).
Lahousse L, Loth D, Joos G. Statins, systemic inflammation and risk of death in chronic obstructive pulmonary disease: the Rotterdame study. Pulm. Pharmacol. Ther. 2013; 26: 212–217.
Liao H. K., Laufs U. Plеotropic effects of statin. Ann.Rev. Pharmacol.Toxic. 2005; 45: 89–118.
Tandon V., Bano G., Khagjuria V. Pleotropic effects of statins. Indian J. Pharmacol. 2005; 2 (37): 77–85.
Yong R. P., Hopkins R., Eaton T. E. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 1–11.
Copyright (c) 2018 The Journal of V. N. Karazin Kharkiv National University, series "Medicine"
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
